Pluripotent stem cells and tolerance induction in organ transplantation

Imberti, Barbara; Monti, Manuela; Casiraghi, Federica

doi:10.1097/mot.0000000000000144

Cited by 16 publications

(9 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Early studies of hESC demonstrated low levels of HLA class I antigens, with a modest induction during differentiation, and absence of HLA class II 12 , 13 . Similar results have been reported for hiPSC 14 . In a recent study, including both hESC and hiPSC lines, Chen et al .…”

Section: Introductionsupporting

confidence: 91%

HLA and Histo-Blood Group Antigen Expression in Human Pluripotent Stem Cells and their Derivatives

Säljö

Barone

Mölne

et al. 2017

Sci Rep

View full text Add to dashboard Cite

One prerequisite for a successful clinical outcome of human pluripotent stem cell (hPSC) based therapies is immune compatibility between grafted cells/tissue and recipient. This study explores immune determinants of human embryonic stem cell lines (hESC) and induced human pluripotent stem cell (hiPSC) lines and hepatocyte- and cardiomyocyte-like cells derived from these cells. HLA class I was expressed on all pluripotent hPSC lines which upon differentiation into hepatocyte-like cells was considerably reduced in contrast to cardiomyocyte-like cells which retained class I antigens. No HLA class II antigens were found in the pluripotent or differentiated cells. Histo-blood group carbohydrate antigens SSEA-3/SSEA-4/SSEA-5, Globo H, A, Lex/Ley and sialyl-lactotetra were expressed on all hPSC lines. Blood group AB(O)H antigen expression was in accordance with ABO genotype. Interestingly, only a subpopulation of A1O1 cells expressed A. During differentiation of hPSC, some histo-blood group antigens showed congruent alteration patterns while expression of other antigens differed between the cell lines. No systematic difference in the hPSC cell surface tissue antigen expression was detected. In conclusion, hPSC and their derivatives express cell surface antigens that may cause an immune rejection. Furthermore, tissue antigen expression must be established for each individual stem cell line prior to clinical application.

show abstract

Section: Introductionsupporting

confidence: 91%

HLA and Histo-Blood Group Antigen Expression in Human Pluripotent Stem Cells and their Derivatives

Säljö

Barone

Mölne

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Successful PSC-based therapy will also require limiting the risk of immune response to PSC derivatives. Although PSCs display some level of immuno privilege as they express low levels of major histocompatibility complex (MHC)I, lack MHCII and co-stimulatory molecules, it is currently clear that both undifferentiated ESCs and iPSCs, as well as their derivatives, can be rejected after transplantation into an immune-competent recipient (for review see Imberti et al 2015 ). Experiments performed with the use of humanized mice reconstituted with a functional human immune system revealed that even in case of autologous transplantation, iPSCs can induce an immune response leading to cell rejection (Zhao et al 2015 ).…”

Section: Discussionmentioning

confidence: 99%

From pluripotency to myogenesis: a multistep process in the dish

Świerczek

Ciemerych

Archacka

2015

J Muscle Res Cell Motil

View full text Add to dashboard Cite

Pluripotent stem cells (PSCs), such as embryonic stem cells or induced pluripotent stem cells are a promising source of cells for regenerative medicine as they can differentiate into all cell types building a mammalian body. However, protocols leading to efficient and safe in vitro generation of desired cell types must be perfected before PSCs can be used in cell therapies or tissue engineering. In vivo, i.e. in developing mouse embryo or teratoma, PSCs can differentiate into skeletal muscle, but in vitro their spontaneous differentiation into myogenic cells is inefficient. Numerous attempts have been undertaken to enhance this process. Many of them involved mimicking the interactions occurring during embryonic myogenesis. The key regulators of embryonic myogenesis, such as Wnts proteins, fibroblast growth factor 2, and retinoic acid, have been tested to improve the frequency of in vitro myogenic differentiation of PSCs. This review summarizes the current state of the art, comparing spontaneous and directed myogenic differentiation of PSCs as well as the protocols developed this far to facilitate this process.

show abstract

“…Kök hücreler, T hücre aktivasyonunu ve proliferasyonunu inhibe ederek olgun dendritik hücrelerin TNF-α ve IFN-γ salgılamalarını azaltıp immün düzenleyici sitokinlerden IL-10 ve IL-4 salgılanması ve regülatör T hücre (Treg) düzeyini artırarak immün düzenleyi-ci bir etki yapmaktadırlar (15) . Solid organ naklinde özellikle böbrek, karaciğer ve diğer organ nakillerinde kök hücrelerin kullanıldığı oldukça fazla çalışma bulunmaktadır.…”

Section: Hücre Ve Organ Transplantasyonuunclassified